Xetra
11.08.26 | 17:35
178,16 Euro
-1,07 % -1,92
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 177,48 | 177,84 | 11.08. | |
| 176,00 | 177,36 | 11.08. |
► 11.08.: | | | | | | | | |
► 10.08.: | | | | | | | | | 17:30
► Aktueller BIOGEN Börsenkurs + Xetra-Orderbuch
► 10.08.: | | | | | | | | | 17:30
► Aktueller BIOGEN Börsenkurs + Xetra-Orderbuch
| Stück | Geld | Kurs | Brief | Stück |
|---|---|---|---|---|
| 178,80 | 24 | |||
Quelle: [URL] https://aktienkurs-orderbuch.finanznachrichten.de/idp.htm [/URL] | ||||
| 24 | 178,20 | |||
| 1.023 | 0,000 | |||
| Summe Aktien im Kauf | Verhältnis | Summe Aktien im Verkauf | ||
| 1.047 | 0,023 | 24 | ||
| Uhrzeit | Aktienkurs | Stück |
|---|---|---|
| 16:30:54 | 176,76 | 2 |
| Tagesumsatz Xetra | -1,92 -1,07 % | 2 |
Angaben in grüner Schrift zeigen, dass der Aktienkurs im Vergleich zum vorherigen Kurs gestiegen ist. Angaben in roter Schrift zeigen gefallene Börsenkurse.
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Biogen Completes RayThera Acquisition | 3 | Contract Pharma | ||
| BIOGEN Aktie jetzt für 0€ handeln | |||||
| Fr | Biogen completes acquisition of immunology firm RayThera | 7 | Investing.com | ||
| Fr | Biogen Inc.: Biogen Completes Acquisition of RayThera Inc. | 603 | GlobeNewswire (Europe) | Lead program now in Phase 1 developmentCAMBRIDGE, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced the completion of the acquisition of RayThera Inc., a privately... ► Artikel lesen | |
| Do | IDEC Corp Bottom Line Rises In Q1 | 13 | RTTNews | ||
| 30.07. | Canaccord raises Biogen stock price target to $248 on strong quarter | 5 | Investing.com |
1 2 3 4 5 Weiter >>
366 Nachrichten in den letzten 12 Monaten
| Zeit | Aktuelle Nachrichten | Medien | ||
|---|---|---|---|---|
| Di | Microbot Medical Inc.: Microbot Medical Files 10-Q, Reports Significant Revenue and Customer Growth During the 2026 Second Quarter | GlobeNewswire (Europe) | Revenue increased by more than 100% over the prior fiscal quarter, driven by repeat orders, expanded utilization among existing customers, and the acquisition of new customers since the Full Market... ► Artikel lesen | |
| Di | Clearmind Medicine Inc.: Clearmind Medicine Announces Positive Permeation Results for Intranasal MEAI Formulation, Supporting Enhanced Nasal Retention Without Compromising Drug Delivery | GlobeNewswire (Europe) | Vancouver, Canada, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND, FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on the discovery and... ► Artikel lesen | |
| Di | Arch Biopartners to Expand Phase II Cardiac Surgery-Associated Acute Kidney Injury Trial to the United States | GlobeNewswire (Europe) | TORONTO, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (TSX Venture: ARCH and OTCQB: ACHFF) today announced that the Company will expand its ongoing Phase II trial of LSALT peptide targeting... ► Artikel lesen | |
| Di | PDS Biotechnology Corporation: PDS Biotech Announces Strategic Refocus Prioritizing PDS0301 in Metastatic Colorectal Cancer (mCRC) and Partnership Strategy for PDS0101 | GlobeNewswire (Europe) | PRINCETON, N.J., Aug. 11, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) ("PDS Biotech" or the "Company"), a late-stage immunotherapy company focused on developing targeted... ► Artikel lesen | |
| Di | Vor Biopharma: Vor Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update | GlobeNewswire (Europe) | Enrollment on track for Phase 3 UPSTREAM MG trial of telitacicept in generalized myasthenia gravis patients with topline results anticipated in 1H27 Enrollment ongoing for Phase 3 UPSTREAM SjD of... ► Artikel lesen |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIOGEN INC finden Sie auf Wallstreet Online.